📢 Breaking News in Oncology!
The NMPA has conditionally approved #Zeprumetostat Tablets (#Airuijing) by Jiangsu Hengrui Pharmaceuticals.

#JiangsuHengrui #InnovationDrug #PeripheralTCellLymphoma #RrPTCL #RelapsedCancer #RefractoryCancer #EZH2Inhibitor #TargetedTherapy #NMPA
#HongKongDengYueMedicine